The USA’s Puma Biotechnology (Nasdaq: PBYI) was up by 8.5% at $93.40 in the opening moments of Tuesday’s trading after the US Food and Drug Administration (FDA) approved Nerlynx (neratinib) for extended adjuvant treatment of HER2-positive early-stage breast cancer.
This makes neratinib the first anti-HER2 treatment to be FDA-approved as extended adjuvant therapy for early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy.
The unmet medical need is significant, as up to 25% of HER2-positive early-stage breast cancer patients treated with trastuzumab-based adjuvant treatment, experience a recurrence.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze